MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS
申请人:Combs Andrew Paul
公开号:US20090286778A1
公开(公告)日:2009-11-19
The present invention relates to macrocyclic compounds of Formula I:
or pharmaceutically acceptable salts thereof or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are JAK/ALK inhibitors useful in the treatment of JAK/ALK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.
Macrocyclic compounds and their use as kinase inhibitors
申请人:Combs Andrew Paul
公开号:US08871753B2
公开(公告)日:2014-10-28
The present invention relates to macrocyclic compounds of Formula I:
or pharmaceutically acceptable salts thereof or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are JAK/ALK inhibitors useful in the treatment of JAK/ALK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.
Syntheses of [<sup>11</sup>C]2- and [<sup>11</sup>C]3-trifluoromethyl-4-aminopyridine: potential PET radioligands for demyelinating diseases
作者:Karla M. Ramos-Torres、Yu-Peng Zhou、Bo Yeun Yang、Nicolas J. Guehl、Moon Sung-Hyun、Sanjay Telu、Marc D. Normandin、Victor W. Pike、Pedro Brugarolas
DOI:10.1039/d0md00190b
日期:——
Trifluoromethyl groups are of great interest in PET radiopharmaceuticals. Radiolabelled 4-aminopyridine (4AP) derivatives have been proposed for imaging demyelinating diseases. Here, we describe methods for producing 11C-trifluoromethylated derivatives of 4AP and present early imaging results with [11C]3-trifluoromethyl-4AP in a rhesus macaque. This study shows the utility of [11C]CuCF3 for labelling